Foxo Technologies Inc. Announces Restructuring And Capital Raising Transactions And Appoints Seamus Lagan As CEO; Key Transactions Include: Rennova Health's Exchange Of ~$21M Of A Senior Secured Note, Into 21,000 Shares Of The Company's Series A...
Foxo Technologies Inc. Announces Restructuring And Capital Raising Transactions And Appoints Seamus Lagan As CEO; Key Transactions Include: Rennova Health's Exchange Of ~$21M Of A Senior Secured Note, Into 21,000 Shares Of The Company's Series A...
Foxo Technologies Inc. 宣佈進行重組和融資交易,並任命 Seamus Lagan 爲首席執行官;主要交易包括:Rennova Health 交換約2100萬美元的高級擔保票據,兌換公司A系列的21000股...
Foxo Technologies Inc. Announces Restructuring And Capital Raising Transactions And Appoints Seamus Lagan As CEO; Key Transactions Include: Rennova Health's Exchange Of ~$21M Of A Senior Secured Note, Into 21,000 Shares Of The Company's Series A Cumulative Convertible Redeemable Preferred Stock; An Institutional Investor's Additional Funding Of $1M And Exchange Of $2.2M Of Senior Notes
Foxo Technologies Inc. 宣佈重組和融資交易,並任命Seamus Lagan爲首席執行官;主要交易包括:Rennova Health 交易約2100萬的高級擔保票據,轉換爲公司 21000 股 A系列累積可轉換可贖回優先股;一位機構投資者額外資助100萬和交換220萬的高級票據
FOXO Technologies Inc. (NYSE American: FOXO) (the "Company" or "FOXO") announces a series of restructuring and capital raising transactions which will improve the Company's balance sheet, satisfy minimum stockholders' equity requirements of the NYSE American and provide capital for growth and reduce outstanding liabilities. The Company also announces a change in senior leadership.
FOXO Technologies Inc. (紐交所美國: FOXO)("公司"或"FOXO")宣佈系列重組和融資交易,這將改善公司的資產負債表,滿足紐交所美國的最低股東權益要求,併爲增長提供資本、減少未償債務。公司還宣佈高層領導變更。
Key transactions include:
主要交易包括:
- Rennova Health, Inc.'s exchange of approximately $21 million of a Senior Secured Note issued by Rennova Community Health, Inc., the Company's subsidiary, into 21,000 shares of the Company's Series A Cumulative Convertible Redeemable Preferred Stock
- An institutional investor's additional funding of $1.0 million and exchange of $2.2 million of Senior Notes (which includes the $1.0 million of additional funding) into 2,464 shares of the Company's Series A Preferred Stock
- Settlement of certain liabilities owed to KR8, Inc. and the termination of a current license agreement for 3,000 shares of the Company's newly designated Series D Cumulative Convertible Redeemable Preferred Stock
- Settlement of certain liabilities owed to KR8, Inc. and the termination of a current license agreement for 3,000 shares of the Company's newly designated Series D Cumulative Convertible Redeemable Preferred Stock
- Rennova Health, Inc. 交換由Rennova Community Health, Inc.(公司的子公司)發行的約2100萬的高級擔保票據,轉換爲公司21000股A系列累積可轉換可贖回優先股
- 一位機構投資者額外資助100萬,並將220萬的高級票據(包括100萬的額外資助)轉換爲公司2,464股A系列優先股
- 解決欠KR8, Inc.的某些債務,以及終止針對公司3,000股新指定的D系列累積可轉換可贖回優先股的當前許可證協議
- 解決欠KR8, Inc.的某些債務,以及終止針對公司3,000股新指定的D系列累積可轉換可贖回優先股的當前許可證協議
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。